March 26, 2019
Nihon Medi-Physics' Strategic Move for Contribution to Cancer Treatment
December 17, 2018
Nihon Medi-Physics Co., Ltd and Norwegian Startup Mentis Cura AS Enter into an Exclusive Agreement to Accelerate Clinical Development of Mentis Cura AS's Proprietary AI-based Software as Novel Dementia Diagnosis EEG Bbiomarker in Japan
November 29, 2018
Telix and Nihon Medi-Physics to Collaborate on Actinium Renal Cancer Therapeutics
November 22, 2018
Global Medical Solutions Taiwan Signs FACBC Joint Development and Distribution Agreement with Nihon Medi-Physics to Develop and Commercialize FACBC, a new PET Imaging Agent, for the Diagnosis of Recurrent Prostate Cancer in Taiwan
August 16, 2018
Telix and Nihon Medi-Physics to Collaborate on Renal Cancer Imaging for the Japanese Market
About the contents of this website
Product information in this Website is provided to offer general information on the Company’s pharmaceutical products. It is not intended to provide medical advice or usage descriptions of the Company’s pharmaceutical products. This Website is not to be used as an alternative for medical practitioners such as physicians and pharmacists to consult with patients in order to determine medical treatments. In addition, the information about the products (including products under development) on this Website does not constitute a promotion or commercial advertisement of the product or its efficacy.
Product information provided on this Website is intended for medical practitioners for use in Japan, and the contents therein are based on approvals that have been granted in Japan. If you are accessing this Website from outside of Japan, please be aware that the product information available on this Website might not be appropriate for you. Please confirm the approval status and content in your relevant country.